Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice

Vaccine

Volumn 24, Issue 21, 2006, Pages 4510-4523

  Egan, Michael A ^a   Megati, Shakuntala ^a   Roopchand, Vidia ^a   Garcia Hand, Dorys ^a   Luckay, Amara ^a   Chong, Siew Yen ^a   Rosati, Margherita ^b   Sackitey, Solomon ^a   Weiner, David B ^c   Felber, Barbara K ^b   Pavlakis, George N ^b   Israel, Zimra R ^a   Eldridge, John H ^a   Sidhu, Maninder K ^a  

^a WYETH RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HIV 1; Mice; Plasmid DNA vaccine; Triple promoter plasmid

Indexed keywords

ASSEMBLIN; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; MEMBRANE PROTEIN; NEF PROTEIN; PLASMID DNA; POL PROTEIN; PROTEIN LAP1; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG MIXTURE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HERPES SIMPLEX VIRUS; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIV ANTIGENS; HIV-1; IMMUNITY, CELLULAR; MICE; PLASMIDS; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; VACCINES, DNA;

EID: 33747091632     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.024     Document Type: Article

References (40)

1. WHO. AIDS epidemic update, December 2004.
2. Wolff J.A., Malone R.W., Williams P., et al. Direct gene transfer into mouse muscle in vivo. Science 247 (1990) 1465-1468
3. Tang D.C., De Vit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 (1992) 152-154
4. Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
5. Sedegah M., Hedstrom R., Hobart P., and Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. PNAS 91 (1994) 9866-9870
6. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Ann Rev Immunol 15 (1997) 617-648
7. Babiuk L.A., van Drunen Littel-van den H., and Babiuk S.L. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopath 72 (1999) 189-202
8. Egan M.A., Charini W.A., Kuroda M.J., et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 74 (2000) 7485-7495
9. MacGregor R.R., Boyer J.D., Ciccarelli R.B., Ginsberg R.S., and Weiner D.B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data [comment]. J Infect Dis 181 (2000) 406
10. Le T.P., Coonan K.M., Hedstrom R.C., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18 (2000) 1893-1901
11. Boyer J.D., Cohen A.D., Vogt S., et al. Vaccination of seronegative volunteers with a human immunodeficiency virus Type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 181 (2000) 476-483
12. Wang R., Epstein J., Baraceros F.M., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. PNAS 98 (2001) 10817-10822
13. Robinson H.L., Montefiori D.C., Johnson R.P., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5 (1999) 526-534
14. Amara R.R., Villinger F., Altman J.D., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
15. Shiver J.W., Fu T.M., Chen L., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
16. Egan MA, Chong S-Y, Megati S, et al. Priming with Plasmid DNAs Expressing IL-12 and SIV Gag Protein Enhances the Immunogenicity and Efficacy of an Experimental AIDS Vaccine Based on Recombinant Vesicular Stomatitis Virus. AIDS Res Human Retroviruses 2005, in press.
17. Koup R., Safrit J., Cao Y., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 (1994) 4650-4655
18. Schneider R., Campbell M., Nasioulas G., Felber B., and Pavlakis G. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 (1997) 4892-4903
19. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 66 (1992) 7176-7182
20. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66 (1992) 150-159
21. Loeb D.D., Swanstrom R., Everitt L., Manchester M., Stamper S.E., and Hutchison III C.A. Complete mutagenesis of the HIV-1 protease. Nature 340 (1989) 397-400
22. Wu X., Liu H., Xiao H., Conway J., and Kappes J. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J Virol 70 (1996) 3378-3384
23. Larder B.A., Purifoy D.J., Powell K.L., and Darby G. Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 327 (1987) 716-717
24. Larder B.A., Kemp S.D., and Purifoy D.J.M. Infectious potential of human immunodeficiency virus Type 1 reverse transcriptase mutants with altered inhibitor sensitivity. PNAS 86 (1989) 4803-4807
25. Davies II J.F., Hostomska Z., Hostomsky Z., Jordan S.R., and Matthews D.A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252 (1991) 88-95
26. Schatz O., Cromme F.V., Gruninger-Leitch F., and Le Grice S.F.J. Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function. FEBS Lett 257 (1989) 311-314
27. Wiskerchen M., and Muesing M. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 69 (1995) 376-386
28. Leavitt A., Shiue L., and Varmus H. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J Biol Chem 268 (1993) 2113-2119
29. Aiken C., Konner J., Landau N.R., Lenburg M.E., and Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76 (1994) 853-864
30. Sadaie M.R., Rappaport J., Benter T., Josephs S.F., Willis R., and Wong-Staal F. Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor. PNAS 85 (1988) 9224-9228
31. HIV Immunology and HIV/SIV Vaccine Databases, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, 2003.
32. Shaw K.J., Rather P.N., Hare R.S., and Miller G.H. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57 (1993) 138-163
33. Sadaie Y., Burtis K.C., and Doi R.H. Purification and characterization of a kanamycin nucleotidyltransferase from plasmid pUB110-carrying cells of Bacillus subtilis. J Bacteriol 141 (1980) 1178-1182
34. Pachuk C.J., Ciccarelli R.B., Samuel M., et al. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine. Biochimica et Biophysica Acta 1468 (2000) 20-30
35. Schmitz J.E., Kuroda M.J., Santra S., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
36. Barouch D.H., Santra S., Schmitz J.E., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (2000) 486-492
37. Lichterfeld M., Yu X.G., Cohen D., et al. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 18 (2004) 1383-1392
38. Kaufmann D.E., Bailey P.M., Sidney J., et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 78 (2004) 4463-4477
39. Frahm N., Korber B.T., Adams C.M., et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78 (2004) 2187-2200
40. Draenert R., Verrill C.L., Tang Y., et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 78 (2004) 630-641